BN

BRAIN Biotech AGMUN BRAIN Stock Report

Last reporting period 31 Mar, 2024

Updated —

Last price

Market cap $B

0.057

Micro

Exchange

XMUN - Boerse Muenchen

BNN.MU Stock Analysis

BN

Uncovered

BRAIN Biotech AG is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-19/100

Low score

Market cap $B

0.057

Dividend yield

Shares outstanding

21.848 B

BRAIN Biotech AG is a technology company, which engages in the development and commercialization of bioactives, natural compounds, and proprietary enzymes. The company is headquartered in Zwingenberg, Hessen and currently employs 307 full-time employees. The company went IPO on 2016-02-09. Research & Development activities focus on bioactive natural compounds, tailored enzymes and high-performance microorganisms.

View Section: Eyestock Rating